Logo

Mundipharma Signs an Exclusive Commercialization and Distribution Agreement with Biosolution in South Korea

Share this

Mundipharma Signs an Exclusive Commercialization and Distribution Agreement with Biosolution in South Korea

Shots:

  • Mundipharma to get exclusive rights to market and distribute Biosolution's CartiLife in South Korea. In May 2016- the companies signed commercialization agreement for allogeneic keratinocyte cell therapy product- KeraHeal-Allo and is the second agreement signed presently
  • The focus of the agreement is to include Biosolution’s CartiLife in the Mundipharma’s portfolio of orthopedic care
  • CartiLife is a fourth-generation autologous cartilage-derived chondrocyte cell therapy targeted to treat cartilage defects (ICRS grade 3 or 4) involved in reduction of host-immune rejection due to its autologous nature with restoration of hyaline cartilage causing less invasion surgery

Click here to read full press release/ article | Ref: PRNewswire | Image: Evaluate


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions